CLINICAL TRIALS PROFILE FOR KAPVAY
✉ Email this page to a colleague
All Clinical Trials for Kapvay
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00588354 ↗ | Epidural Clonidine for Lumbosacral Radiculopathy | Terminated | National Center for Research Resources (NCRR) | N/A | 2006-10-01 | This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition. |
| NCT00588354 ↗ | Epidural Clonidine for Lumbosacral Radiculopathy | Terminated | Mayo Clinic | N/A | 2006-10-01 | This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition. |
| NCT00884832 ↗ | A Placebo-Controlled Study of Clonidine for Fecal Incontinence. | Completed | National Center for Research Resources (NCRR) | Phase 2 | 2008-10-01 | Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women. |
| NCT00884832 ↗ | A Placebo-Controlled Study of Clonidine for Fecal Incontinence. | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2008-10-01 | Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Kapvay
Condition Name
| Condition Name for Kapvay | |
| Intervention | Trials |
| Attention Deficit Hyperactivity Disorder | 1 |
| Fecal Incontinence | 1 |
| Lumbar and Other Intervertebral Disc Disorders With Radiculopathy | 1 |
| Opiate Addiction | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Kapvay
Trials by Country
Clinical Trial Progress for Kapvay
Clinical Trial Phase
Clinical Trial Sponsors for Kapvay
Sponsor Name
